The Biological Function and Tumorigenesis Of ERK/MAPK Signaling in Melanoma

Authors

  • Lingyi Jiang

DOI:

https://doi.org/10.54097/ksfqbk98

Keywords:

Melanoma, ERK, MAPK, tumorigenesis, cancer.

Abstract

Melanoma, as a potentially lethal malignant tumor, has been increasing worldwide. As an aggressive and lethal skin cancer, discover the malignant melanoma at an early stage can reduce mortality. The deeper the tumor, the more difficult the prognosis of the melanoma, Timely detection and rapid treatment of melanoma is very important for the diagnosis of melanoma. Because the treatment of melanoma is resistant to conventional chemotherapy, the direction of treatment has shifted to molecular targeted therapy. The MAPK pathway is a central signal transduction element that regulates basic physiological activities such as cell proliferation and apoptosis, the occurrence and development of tumors. The over-activation of ERK Assume a pivotal role. RAS/Raf/MAPK (MEK) /ERK pathway is a part of the MAPK signaling pathway, which is the most pivotal signaling cascade. RAS/Raf/ MEK/ERK (MAPK) pathway inhibitors have shown significant results in the clinical treatment of tumors, and can slow the development of the disease. In this review, we discussed the principles, methods and recent progress in the targeted therapy of melanoma.of the ERK/MAPK pathway.

Downloads

Download data is not yet available.

References

Sera F, Gandini S, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2015, 41: 45-60.

Lejeune FJ. Epidemiology and etiology of malignant melanoma. Biomed Pharmacother. 1986;40(3):91-9.

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020 Mar;19(3):1997-2007.

Davies H., Bignell G.R., et al. Mutations of the BRAF gene in human cancer. Nature. 2002, 417:949–954.

Nissan M.H., Pratilas C.A., et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 2014, 74:2340–2350.

Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular Markers and Targets in Melanoma. Cells. 2021 Sep 5;10(9):2320.

Grimaldi AM, Simeone E, Ascierto PA. The role of MEK inhibitors in the treatment of metastatic melanoma. Curr Opin Oncol. 2014 Mar;26(2):196-203.

Queirolo P, Picasso V, Spagnolo F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev. 2015 Jun;41(6):519-26.

Grimaldi AM, et al. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Discov Med. 2015 Jun;19(107):455-61.

Marchetti P, Trinh A, Khamari R, Kluza J. Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors. Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):999-1005.

Savoia, P.; Fava, P.; Casoni, F.; Cremona, O. Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci. 2019, 20, 1483.

Downloads

Published

29-12-2023

How to Cite

Jiang, L. (2023). The Biological Function and Tumorigenesis Of ERK/MAPK Signaling in Melanoma. Highlights in Science, Engineering and Technology, 74, 908-912. https://doi.org/10.54097/ksfqbk98